AQUAPASS Receives Significant Marketing Approval
AQUAPASS, a trailblazer in non-invasive fluid management technologies, has reached a major milestone by obtaining marketing approval for its AQUAPASS System in Israel. This achievement signifies an important step towards introducing innovative therapeutic solutions for patients struggling with fluid overload conditions.
Commercial Rollout and Collaboration
In an exciting development, AQUAPASS is set to begin its commercial rollout across selected medical centers in Israel. This initiative will involve close collaboration with top clinicians to gather clinical feedback and accumulate real-world evidence that will facilitate broader adoption and seamless integration of the AQUAPASS System into various patient care frameworks.
Clinical Trials and Ongoing Research
The ongoing pivotal REFORM-HF trial is currently evaluating the AQUAPASS system's efficacy. This trial includes participation from leading hospitals across the U.S. and Israel, focusing on patients diagnosed with acutely decompensated heart failure. These patients often struggle to respond to conventional treatment methods, and the AQUAPASS system aims to provide an essential alternative. The trial outcomes are anticipated to greatly inform future integration into clinical practice, with completion goals firmly set for early 2026.
The approval opens up versatile clinical indications for use across critical domains including cardiology, nephrology, and general medicine, emphasizing support for both acute and chronic patient demographics.
Leadership Insights
Noam Josephy, CEO of AQUAPASS, expressed his enthusiasm for the approval, stating, "This is a pivotal transition for AQUAPASS, moving from bench to bedside. Our mission is to assist patients enduring acute and chronic ailments. This accomplishment resonates with our dedicated team, enhancing our ambition to redefine fluid overload management and therapeutic approaches."
Expert Opinions on the Approval
Medical professionals are equally optimistic about the AQUAPASS System's potential. Prof. Doron Aronson from the Rambam Medical Center highlighted the pressing issues surrounding fluid overload among cardiac patients. He stated, "The AQUAPASS System provides an essential, non-invasive method that could revolutionize patient management both within hospital environments and beyond."
Furthermore, comments from Prof. Ron Wald, a notable nephrologist, emphasize the system's groundbreaking capabilities for patients facing advanced chronic kidney disease. He noted, "This non-invasive technology can facilitate safe fluid removal without reliance on traditional diuretic methods, representing a major advancement in managing kidney issues."
Advancing Global Strategy
The recent approval underlines AQUAPASS's transition into a commercial-phase organization and lays the groundwork for its broader international growth strategy. The company is committed to advancing its clinical trial endeavors, preparing for FDA submissions anticipated for early 2026. Meanwhile, AQUAPASS has also received two FDA Breakthrough Device Designations, highlighting its status as a front-runner in non-invasive fluid management solutions.
About AQUAPASS
AQUAPASS is dedicated to developing innovative, non-invasive solutions catering to fluid overload management for patients dealing with heart failure and chronic kidney disease. Its advanced technology facilitates the efficient and safe removal of excess fluid directly from the interstitial space, independent of kidney function, which aims to enhance patient outcomes and improve quality of life overall.
Frequently Asked Questions
What is the AQUAPASS System?
The AQUAPASS System is a non-invasive technology designed to manage fluid overload in patients, offering an alternative to traditional methods that often rely on diuretics.
Where has AQUAPASS received marketing approval?
AQUAPASS has received marketing approval in Israel, enabling the system's introduction to local medical facilities.
What is the focus of the ongoing REFORM-HF trial?
The REFORM-HF trial primarily evaluates the effectiveness of the AQUAPASS System in patients with acutely decompensated heart failure who have not responded well to current therapies.
What are the anticipated completion dates for the clinical trial?
Enrollment completion for the trial is targeted for early 2026, with an FDA submission also planned for the second quarter of 2026.
How does AQUAPASS plan to expand globally?
The approval in Israel sets the stage for AQUAPASS's international growth strategy, paving the way for further deployments and collaborations worldwide.
